Name: Liminatus Pharma, Inc. (LIMN) Financial Statements
Creator: FinSpry

Liminatus Pharma Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

Liminatus Pharma, Inc. income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Revenue & Gross Profit
Revenue	0.00	0.00	0.00	0.00
Cost of Revenue	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00
Operating Expenses
Research & Development	2.69	3.76	1.85	3.80
Selling, General & Administrative	0.65	1.06	0.86	0.20
Operating Expenses	2.91	4.82	2.71	4.00
Operating Income	-2.91	-4.82	-2.71	-4.00
Other Income/Expense
Interest Income	0.14	0.01	0.00	0.00
Interest Expense	0.14	0.18	-0.22	-1.61
Other Income/Expense	0.02	0.00	0.00	0.00
Income
Income Before Tax	-2.89	-4.98	-2.93	-5.61
Income Tax Expense	0.02	0.00	0.00	0.00
Net Income	-2.90	-4.98	-2.93	-5.61
Net Income - Continuous Operations	-2.90	-4.98	-2.93	0.00
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00
EBITDA	-2.75	-4.81	-2.71	-4.00
EBIT	-3.33	-4.81	-2.71	-4.00
Depreciation & Amortization	0.00	0.00	0.00	0.00
Earnings Per Share
Basic EPS	-	-	-	-
Diluted EPS	-	-	-	-
Basic Shares Outstanding	7.19	26.01	35.56	0.00
Diluted Shares Outstanding	7.19	26.01	35.56	0.00